Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:16:29.721Z.
Consensus retrieved: 2026-10-06T10:56:56.212Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:16:29.721Z.
Quote observation: 2026-10-06T19:15:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 304a80059de762086f201eae28471a3f317e523c87af6f00839e9007cc2266bd
Forward PE Ratio (N/A) = Dated Quote Price ($6.19) / Consensus Forward EPS ($-3.59)
FORWARD PE RATIO
N/A
Precision BioSciences, Inc.
Market Cap
$170.94M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Precision BioSciences, Inc. (DTIL) | $170.94M | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $170.21M | N/A |
| Organogenesis Holdings Inc. (ORGO)vs › | $169.84M | N/A |
| Journey Medical Corporation (DERM)vs › | $173.30M | N/A |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.76M | N/A |
| MediWound Ltd. (MDWD)vs › | $168.97M | N/A |
| Nkarta, Inc. (NKTX)vs › | $165.99M | N/A |
| OptimizeRx Corp. (OPRX)vs › | $165.88M | 9.86 |
| Quanterix Corporation (QTRX)vs › | $163.28M | N/A |
| Yarrow Bioscience Inc (YARW)vs › | $179.76M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $6.19, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-3.59 | $-3.71 – $-3.47 | 3 | n/m |
| 2027-12-31 | $-2.84 | $-3.31 – $-2.37 | 3 | n/m |
| 2028-12-31 | $-1.99 | $-3.09 – $-0.78 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
